Zusammenfassung
Die Therapie des Diabetes mellitus bei Patient:innen mit gleichzeitig bestehender Leberzirrhose stellt eine besondere therapeutische Herausforderung dar. Die Leber ist ein zentrales Organ der Glukosehomöostase und daher sind Erkrankungen, welche mit einer Einschränkung der Leberfunktion einhergehen auch häufig mit Störungen im Glukosemetabolismus vergesellschaftet. Eine Leberzirrhose kann hierbei, je nach aktuellem Krankheitsstadium mit einer ausgeprägten Insulinresistenz oder einem stark erhöhten Hypoglykämierisiko einhergehen. Die Ursachen für diese stark wechselnden Effekte auf den Glukosestoffwechsel sind multifaktoriell und werden durch hepatische und systemische Faktoren verursacht. Die stark eingeschränkten therapeutischen Möglichkeiten zur Behandlung des Diabetes mellitus bei fortgeschrittener Leberzirrhose und die dadurch häufige Notwendigkeit der Insulintherapie spielen hier ebenfalls eine Rolle. Andererseits kann sich eine schlechte glykämische Kontrolle negativ auf den Verlauf von hepatischen Erkrankungen auswirken, sodass eine gute glykämische Kontrolle insbesondere in diesem Kollektiv von großer Bedeutung ist.
Abstract
Therapy of diabetes mellitus in patients with concomitant liver cirrhosis is a special challenge. The liver is a key player in glucose homeostasis. Therefore, disturbances of hepatic metabolism are often accompanied by disorders in glucose metabolism. Depending on the stage of the disease, either pronounced insulin resistance or severe risk of hypoglycemia might accompany liver cirrhosis. The causes are multifactorial and comprise hepatic as well as systemic changes. Limited usability of antidiabetic medication and frequent necessity of insulin usage play an important role, also. Additionally, glycemic control has major impact on development and progression of many hepatic disorders including liver cirrhosis. Therefore, good glycemic control, especially in patients with liver disease, is of major importance.
Literatur
Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N et al (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 71(4):793–801
McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM (2015) Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62(5):1148–1155
de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M (1999) Cause-specific mortality in type 2 diabetes. The verona diabetes study. Diabetes Care 22(5):756–761
Arvanitakis K, Koufakis T, Kalopitas G, Papadakos SP, Kotsa K, Germanidis G (2023) Management of type 2 diabetes in patients with compensated liver cirrhosis: short of evidence, plenty of potential. Diabetes Metab Syndr 28;18(1):102935
García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, Reyes-Cabello E, González-González JA, Muñoz-Espinosa LE et al (2012) The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Ann Hepatol 11(2):240–248
Asrih M, Jornayvaz FR (2015) Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol Cell Endocrinol 418:55–65
Fromenty B, Roden M (2023) Mitochondrial alterations in fatty liver diseases. J Hepatol 78(2):415–429
Champion C, Neagoe RM, Effernberger M, Sala DT, Servant F, Christensen JE et al (2023) Human liver microbiota modeling strategy at the early onset of fibrosis. BMC Microbiol 30;23(1):34
Puri P, Kotwal N (2022) An approach to the management of diabetes mellitus in cirrhosis: A primer for the hepatologist. J Clin Exp Hepatol 12(2):560–574
de Vries M, Westerink J, Kaasjager KHAH, de Valk HW (2020) Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 1;105(12):3842–3853
Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S et al (2023) A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol 78(3):471–478
Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14(1):32–42
Zachou K, Azariadis K, Lytvyak E, Snijders RJALM, Takahashi A, Gatselis NK et al (2023) Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease. Jhep Rep Innov Hepatol 5(8):100778
Wang X, Wei S, Wei Y, Wang X, Xiao F, Feng Y et al (2023) The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study. Eur J Gastroenterol Hepatol 35(8):889–898
Clodi M, Abrahamian H, Brath H, Schernthaner G, Brix J, Ludvik B et al (2023) Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023). Wien Klin Wochenschr 135(Suppl 1):32–44
Tsamos G, Vasdeki D, Koufakis T, Michou V, Makedou K, Tzimagiorgis G (2023) Therapeutic potentials of reducing liver fat in non-alcoholic fatty liver disease: close association with type 2 diabetes. Metabolites 4;13(4):517
Dixon JB, Bhathal PS, O’Brien PE (2006) Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. OBES SURG 16(10):1278–1286
Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, Raverdy V et al (2014) Roux-en‑Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 260(5):893–898
Zm Y, Ke C, Jk L (2021) AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology 160(3)
Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T et al (2019) ESPEN guideline on clinical nutrition in liver disease. Clin Nutr Edinb Scotl 38(2):485–521
Calmet F, Martin P, Pearlman M (2019) Nutrition in patients with cirrhosis. Gastroenterol Hepatol 15(5):248–254
Akiyama H, Nishimura A, Morita N, Yajima T (2023) Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. Front Endocrinol 14:1111984
B L, Y W, Z Y, H Y, X C, Z W et al (2018) Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. J Pharm Pharm Sci Publ Can Soc Pharm Sci Soc Can Sci Pharm [internet] 21(1)
Arai T, Atsukawa M, Tsubota A, Mikami S, Haruki U, Yoshikata K et al (2022) Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun 6(11):3073–3082
Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Babaei RM et al (2020) Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther 37(11):4697–4708
Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet Lond Engl 387(10019):679–690
Lee HA, Kim HY (2023) Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease. Int J Mol Sci 26;24(11):9324
Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C et al (2016) Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165(5):305–315
Ndakotsu A, Vivekanandan G (2022) The role of thiazolidinediones in the amelioration of nonalcoholic fatty liver disease: a systematic review. Cureus 14(5)
Zhang A, Qian F, Li Y, Li B, Yang F, Hu C et al (2023) Research progress of metformin in the treatment of liver fibrosis. Int Immunopharmacol 116:109738
Yang T, Guan Q, Shi JS, Xu ZH, Geng Y (2023) Metformin alleviates liver fibrosis in mice by enriching Lactobacillus sp. MF‑1 in the gut microbiota. Biochim Biophys Acta Mol Basis Dis 1869(5):166664
Su Y, Hou C, Wang M, Ren K, Zhou D, Liu X et al (2023) Metformin induces mitochondrial fission and reduces energy metabolism by targeting respiratory chain complex I in hepatic stellate cells to reverse liver fibrosis. Int J Biochem Cell Biol 157:106375
Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A et al (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 1;19(5):537–544
Yen FS, Huang YH, Hou MC, Hwu CM, Lo YR, Shin SJ et al (2022) Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis. Br J Clin Pharmacol 88(1):311–322
Maaly AE, Haidy K, Shahinaz S (2021) Hepatoprotective effect of linagliptin against liver fibrosis induced by carbon tetrachloride in mice. Can J Physiol Pharmacol 99(3):294–302. https://doi.org/10.1139/cjpp-2020-0049
Kim NH, Yu T, Lee DH (2014) The nonglycemic actions of dipeptidyl peptidase-4 inhibitors. Biomed Res Int 2014:368703
Petroni ML, Brodosi L, Marchesini G (2023) The treatment of diabetes in advanced liver disease: change of a paradigm. Ann Hepatol 28(1):100772
Yen FS, Hou MC, Liu JS, Hsu CC, Hwu CM (2022) Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes. Front Med 9:962337
Inagaki N, Sheu WHH, Owens DR, Crowe S, Bhandari A, Gong Y et al (2016) Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials. J Diabetes Complications 30(8):1622–1630
Yen FS, Wei JCC, Yip HT, Hwu CM, Hou MC, Hsu CC (2021) Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan. Hepatol Int 15(1):179–190
Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K et al (2010) Linagliptin (BI 1356), a potent and selective DPP‑4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med J Br Diabet Assoc 27(12):1409–1419
Mariam Z, Niazi SK (2024) Glucagon-like peptide agonists: A prospective review. Endocrinol Diabetes Metab 7(1):e462
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
C. Ress gibt an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Hinweis des Verlags
Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Ress, C. Diabetes mellitus bei Patient:innen mit Leberzirrhose – eine besondere therapeutische Herausforderung. J. Gastroenterol. Hepatol. Erkr. (2024). https://doi.org/10.1007/s41971-024-00191-6
Accepted:
Published:
DOI: https://doi.org/10.1007/s41971-024-00191-6